The mTOR pathway has emerged as a focal point in the realm of longevity science. When mTORC1's signals are controlled, it potentially paves the way for a longer, healthier existence. Contrastingly, mTORC2 reveals a more complex tale, with its suppression leading to metabolic complications and decreased survival rates in mice. Rapamycin, a compound frequently highlighted in our previous research reviews, targets this pivotal pathway. The intrigue around rapamycin is rooted in its dual nature: it might extend lifespan and counteract age-related ailments, but it also walks a fine line between the benefits of inhibiting mTORC1 and the risks tied to inadvertently suppressing mTORC2. In this comprehensive analysis, we delve deep into the latest research on rapamycin to elucidate its potential and influence on the most critical markers of longevity and healthspan—highlighting the vital nuances of how dosing influences its potential benefits and side effect profile.